JP Morgan Chase
MACK

JP Morgan Chase’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

JP Morgan Chase’s Portfolio MACK Stock Details MACK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-11,786
Closed -$174K – 7910
2024
Q1 		$174K Buy
11,786
+4,997
+74% +$70.2K ﹤0.01% 5415
2023
Q4 		$91K Buy
6,789
+2
+0% +$25 ﹤0.01% 5779
2023
Q3 		$83.7K Sell
6,787
-1,557
-19% -$18.9K ﹤0.01% 5592
2023
Q2 		$103K Buy
+8,344
New +$104K ﹤0.01% 5444
2023
Q1 		– Sell
-354
Closed -$4K – 7565
2022
Q4 		$4K Buy
+354
New +$2.92K ﹤0.01% 6230
2021
Q3 		– Sell
-525
Closed -$3K – 7082
2021
Q2 		$3K Buy
+525
New +$3.46K ﹤0.01% 6195
2020
Q4 		– Sell
-7
Closed – – 6195
2020
Q3 		$0 Sell
7
-674
-99% -$2.48K ﹤0.01% 6045
2020
Q2 		$2K Sell
681
-10,476
-94% -$35.8K ﹤0.01% 5282
2020
Q1 		$24K Buy
11,157
+732
+7% +$2.14K ﹤0.01% 4911
2019
Q4 		$33K Buy
10,425
+10,325
+10,325% +$41.3K ﹤0.01% 5239
2019
Q3 		$0 Sell
100
-27
-21% -$135 ﹤0.01% 6155
2019
Q2 		$1K Sell
127
-42,286
-100% -$200K ﹤0.01% 5734
2019
Q1 		$232K Sell
42,413
-28,679
-40% -$132K ﹤0.01% 4565
2018
Q4 		$216K Buy
71,092
+1,068
+2% +$3.7K ﹤0.01% 4570
2018
Q3 		$294K Buy
70,024
+69,897
+55,037% +$295K ﹤0.01% 4539
2018
Q2 		$0 Sell
127
-3,736
-97% -$24.8K ﹤0.01% 5877
2018
Q1 		$25K Sell
3,863
-175
-4% -$1.45K ﹤0.01% 5034
2017
Q4 		$32K Buy
4,038
+3,631
+892% +$33.9K ﹤0.01% 5047
2017
Q3 		$4K Buy
407
+43
+12% +$452 ﹤0.01% 4836
2017
Q2 		$3K Sell
364
-28,408
-99% -$580K ﹤0.01% 4835
2017
Q1 		$697K Sell
28,772
-3,639
-11% -$91K ﹤0.01% 3568
2016
Q4 		$1.04M Buy
32,411
+2,738
+9% +$117K ﹤0.01% 3416
2016
Q3 		$1.48M Sell
29,673
-2,448
-8% -$102K ﹤0.01% 2950
2016
Q2 		$1.36M Sell
32,121
-9,725
-23% -$530K ﹤0.01% 3015
2016
Q1 		$2.76M Sell
41,846
-15
-0% -$783 ﹤0.01% 2535
2015
Q4 		$2.6M Sell
41,861
-3,653
-8% -$257K ﹤0.01% 2624
2015
Q3 		$3.05M Buy
45,514
+13,432
+42% +$1.1M ﹤0.01% 2534
2015
Q2 		$3.12M Sell
32,082
-1,407
-4% -$134K ﹤0.01% 2658
2015
Q1 		$3.13M Buy
33,489
+108
+0.3% +$9.19K ﹤0.01% 2631
2014
Q4 		$2.97M Sell
33,381
-10,326
-24% -$752K ﹤0.01% 2733
2014
Q3 		$3.02M Sell
43,707
-918
-2% -$49.1K ﹤0.01% 2661
2014
Q2 		$2.56M Sell
44,625
-3,048
-6% -$155K ﹤0.01% 2405
2014
Q1 		$1.89M Buy
47,673
+4,182
+10% +$179K ﹤0.01% 2573
2013
Q4 		$1.82M Sell
43,491
-6,250
-13% -$181K ﹤0.01% 2813
2013
Q3 		$1.48M Buy
49,741
+5,163
+12% +$181K ﹤0.01% 3002
2013
Q2 		$2.36M Buy
+44,578
New +$1.95M ﹤0.01% 2690

Other funds holding MACK

Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
RA
Rise Advisors Rochester, New York $355M AUM 20.51% 1-Year Est. Return
JC
JBF Capital Aspen, Colorado $676M AUM 24.74% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

JP Morgan Chase's MACK Position: Q2 2024 in Review

JP Morgan Chase sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q2 2024, closing a stake of 11,786 shares — an estimated $174K sold.

JP Morgan Chase first reported a position in MACK in Q2 2013 and held it in 36 quarters. The position peaked at $3.13M in Q1 2015. 12 funds tracked by Wall St. Rank hold MACK as of Q2 2024.

  • JP Morgan Chase reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q2 2024 after selling out during the quarter.
  • JP Morgan Chase sold 11,786 Merrimack Pharmaceuticals, Inc. shares in Q2 2024, an estimated $174K.
  • JP Morgan Chase first reported a position in Merrimack Pharmaceuticals, Inc. in Q2 2013 and held it in 36 quarters.
  • JP Morgan Chase's Merrimack Pharmaceuticals, Inc. position peaked at $3.13M in Q1 2015.
  • 12 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q2 2024.

Based on JP Morgan Chase's 13F filing for Q2 2024, filed 12 Aug 2024.